A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers

NCT01518712 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
DRUG: B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.